Latest news with #medicalTechnology
Globe and Mail
3 days ago
- Business
- Globe and Mail
Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025
CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2025 financial results after market close on Thursday, August 28, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call. Event Date: Thursday, August 28, 2025 Time: 1:30 PM Pacific Time Participant Registration: A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website here. About Carlsmed Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. Investor Relations IR@ Media
Fox News
07-07-2025
- Health
- Fox News
How micro-robots may soon treat your sinus infections
A breakthrough in medical technology could soon change how sinus infections are treated. Scientists have created micro-robots for sinus infection treatment that can enter the nasal cavity, eliminate bacteria directly at the source, and exit without harming surrounding tissue. This drug-free, targeted approach may reduce our dependence on antibiotics. Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide - free when you join my These microscopic robots are smaller than a speck of dust. They are made of magnetic particles enhanced with copper atoms. Doctors insert them through a narrow duct in the nostril. Once inside, the micro-robots are guided by magnetic fields to reach the infected area. At that point, a fiber optic light heats the particles and triggers a chemical reaction. This reaction breaks through thick mucus and destroys harmful bacteria at the infection site. As a result, treatment becomes faster, more precise, and far less invasive. This latest advancement comes from a collaboration of researchers at the Chinese University of Hong Kong, along with universities in Guangxi, Shenzhen, Jiangsu, Yangzhou, and Macau. Their work, published in "Science Robotics," has helped move micro-robotic medical technology closer to real-world applications. Traditional antibiotics circulate throughout the entire body. In contrast, micro-robots target only the infected area. This reduces side effects and lowers the risk of antibiotic resistance. Furthermore, patients may recover faster because the treatment goes straight to the source. So far, animal trials have shown promising results. Micro-robots successfully cleared infections in pig sinuses and live rabbits, without causing tissue damage. However, scientists still need to ensure that every robot exits the body after treatment. Leftover particles could pose long-term risks. In addition, public acceptance remains a challenge. The idea of tiny machines inside the body makes some people uncomfortable. Nevertheless, experts believe those fears will fade over time. Researchers are already exploring how micro-robots could treat infections in the bladder, stomach, intestines, and bloodstream. Several teams around the world are working to make the technology more advanced and adaptable for deep internal use. If successful, these innovations could revolutionize the way we fight bacteria in the human body. The rise of micro-robots for sinus infection treatment marks a major shift in medical care. By offering precise, non-invasive therapy without antibiotics, this method could redefine how infections are treated. With continued research and testing, these tiny tools may soon become powerful allies in modern medicine. Would you let microscopic robots crawl through your sinuses if it meant never needing antibiotics again? Let us know by writing to us at Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide - free when you join my Copyright 2025 All rights reserved.
Reuters
01-07-2025
- Business
- Reuters
Brainlab CEO in internal memo blames geopolitical uncertainties for putting IPO on ice
MUNICH, Germany, July 1 (Reuters) - The CEO of German medical technology firm Brainlab said on Tuesday that geopolitical uncertainties had prompted the decision to put on hold its planned initial public offering, adding that business in the last quarter looked positive. "We have to recognise that the current geopolitical uncertainties continue to have a significant impact on the international capital markets," wrote Rainer Birkenbach in an internal memo seen by Reuters, adding that at this time, an IPO did not offer optimal conditions for the company.
Yahoo
25-06-2025
- Business
- Yahoo
Stryker receives FDA clearance for Incompass Total Ankle System
Streamlining total ankle replacement with data-driven implants and surgical flexibility PORTAGE, Mich., June 25, 2025--(BUSINESS WIRE)--Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker's Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement. "Incompass reflects our commitment to redefining what's possible in total ankle replacement," said Adam Jacobs, vice president and general manager of Stryker's Foot & Ankle business. "By building on decades of clinical experience and leveraging extensive data insights, we're setting a new standard—one that empowers surgeons to deliver more personalized care with greater efficiency and confidence." Incompass incorporates Adaptis® Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow. Developed to address key challenges in total ankle replacement, including intraoperative adaptability and procedural efficiency, the system is informed by data from more than 85,000 CT scans¹ and 100,000 clinical cases.¹ It also offers a broad range of implant and instrumentation options to support patient-specific care. Built using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform in combination with arthritic ankle scans from the company's Prophecy Surgical Planning System, Incompass provides a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy. System enhancements include a redesigned alignment system for greater control across multiple planes, updated implant holders and trial tools for improved handling, and instrumentation refinements designed to reduce surgical steps and set up time. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at Copyright © 2025 StrykerContent ID: FA-INCO-PRESS-2016296 References:1. Based on internal data as of 5/1/2025. View source version on Contacts Media contact Sampson Public Relations GroupAndrea SampsonPresident/CEO asampson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
18-06-2025
- Business
- Associated Press
ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke
BARCELONA, Spain--(BUSINESS WIRE)--Jun 18, 2025-- ANACONDA Biomed, a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has received CE Mark certification for its ANA5 Funnel Catheter. The CE marking confirms that the ANA5 device complies with the European Union's health, safety, and environmental protection standards, enabling its eventual commercial viability across the EU. This press release features multimedia. View the full release here: The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry. The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry. The CE Mark approval is supported by a comprehensive body of evidence, including preclinical bench and animal studies, and clinical data from the recently published ANAIS study demonstrating high reperfusion and first-pass success rates. Further clinical validation is ongoing in the ATHENA trial, a prospective, multicenter randomized study systematically evaluating the impact of proximal flow arrest on reperfusion effectiveness, to support future regulatory submissions and commercialization efforts in the United States. ' Receiving CE Mark approval is a pivotal achievement for ANACONDA Biomed thatadvances our mission to innovate in the interventional management of acute ischemic stroke,' said Trent Reutiman, chief executive officer. " This milestone reflects the strength of our science and the dedication of our team. We now have the capability of making ANA5 available to clinicians across Europe, bringing this innovative technology to broader stroke application.' Dr. Marc Ribo, the co-founder of Anaconda Biomed, added, " Receiving CE Mark approval for ANA5 is deeply meaningful, as it represents the culmination of years of research, iteration, and belief in an idea that began at the bench. This is more than a regulatory milestone; it's the moment where innovation becomes impact. We're now gearing up to capture real-world data by collecting more invaluable insight into how ANA5 performs across diverse stroke centers and clinical realities. ' About ANA Funnel Catheter ANA5 Advanced Neurovascular Access™ (ANA Funnel Catheter) is designed as an expandable and collapsable funnel catheter for interventional neurovascular procedures, requiring the retrieval of clot, and benefiting from limiting flow and/or flow reversal towards that goal. The device consists of a radiopaque nitinol braid funnel, covered with a polymeric coating enabling local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States. About Anaconda Biomed Anaconda Biomed is an innovative medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health. For more information, please visit and follow the company on LinkedIn. View source version on CONTACT: MEDIA CONTACT: Joe Duraes Pazanga Health Communications [email protected] 917-687-6419 KEYWORD: SPAIN EUROPE INDUSTRY KEYWORD: SURGERY MEDICAL DEVICES HEALTH CLINICAL TRIALS CARDIOLOGY SOURCE: Anaconda Biomed Copyright Business Wire 2025. PUB: 06/18/2025 07:05 AM/DISC: 06/18/2025 07:03 AM
